�빐硫댄삁愿�湲고삎 愿��젴 �뇤�쟾利� �솚�옄瑜� ���긽�쑝濡� �븳 �빟臾쇱쟻 移섎즺�쓽 �옣湲곗쟻 �삁�썑 by �씠�쑄二�
Yoonju Lee
Department of Medicine
The Graduate School, Yonsei University
Clinical outcome following medical treatment of 
cavernous malformation related epilepsy
Clinical outcome following medical treatment of 
cavernous malformation related epilepsy
Directed by Professor Byung In Lee
Yoonju Lee
The Master's Thesis 
submitted to the Department of Medicine,
the Graduate School of Yonsei University
in partial fulfillment of the requirements for the degree of
Master of Medical Science
December 2014
This certifies that the Master's Thesis of 
Yoonju Lee is approved.
Thesis Supervisor: Byung In Lee
Thesis Committee Member#1 : Kyoung Heo
Thesis Committee Member#2 : Seung-Koo Lee 
The Graduate School
Yonsei University
December 2014
 ACKNOWLEDGEMENTS 
 
I am honored to thank many grateful benefactors who contributed 
this thesis. In particular, I deeply appreciate supervisor, Prof. 
Byung In Lee for his sincere principles, thorough guidance and 
honest enthusiasm. With great appreciation, I acknowledge Prof. 
Kyoung Heo for endless encouragement, valuable advice and 
support. In addition, I am grateful to be guided by Prof. Seung-
Koo Lee who gave me expert counsel and encouragement to 
complete this thesis. 
I deeply thank my father, mother, sister and husband for patience, 
sacrifice, faith and love for me.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
December 2014 
Yoonju Lee 
- i - 
<TABLE OF CONTENTS> 
ABSTRACT········································································· 1 
 
I. INTRODUCTION ································································ 3 
II. MATERIALS AND METHODS ·············································· 5 
1. Patients and treatment ························································ 5 
2. Evaluations and assessments ················································ 6 
3. Statistics ········································································ 8 
III. RESULTS  ······································································ 8 
1. Demography and Clinical Characteristics ································· 8 
2. Outcome of AEDs Therapy ················································· 10 
3. Clinical variables related with the outcome of AEDs therapy  ········ 11 
4. Postoperative seizure outcome ·············································· 14 
5. Follow-up brain MRI ························································· 15 
IV. DISCUSSION  ································································· 17 
V. CONCLUSION  ································································ 23 
 
REFERENCES  ···································································· 24 
ABSTRACT(IN KOREAN)  ···················································· 28 
  
- ii - 
LIST OF FIGURES 
 
Figure 1. Flowchart of overall seizure outcome  ··················· 11 
 
 
 
 
LIST OF TABLES 
 
 
Table 1. Comparison between characteristics of the Group 1 and 
Group 2 ··································································· 12 
Table 2. Comparison between outcomes of the temporal located 
CM and extratemporal located CM ································ 13 
Table 3. The patients who underwent surgical intervention for CM
 ············································································· 15 
Table 4. The patients whose lesion changed in repeated brain MRI
 ············································································· 16
- 1 - 
<ABSTRACT> 
Clinical outcome following medical treatment of cavernous malformation 
related epilepsy 
 
Yoonju Lee 
 
Department of Medicine  
The Graduate School, Yonsei University 
 
 
(Directed by Professor Byung In Lee) 
 
 
 
Purpose: The study was conducted to assess the long-term outcome of antiepileptic 
drug (AED) treatment in drug-naïve patients with cavernous malformation related 
epilepsy (CRE)  
Methods: This is a retrospective, single-center, long-term observational study. 
Study included patients presented to the epilepsy clinic between 2000 and 2011 with 
previously untreated seizures related to MRI-proven, cavernous malformation (CM). 
All patients were followed-up for at least two years. Previous history of surgical or 
AEDs treatment, lack of EEG examination, no or only a single previous seizure 
were exclusion criteria. Seizure outcome was assessed on annual basis and patients 
were divided into two groups according to the success (Group 1) or failure (Group 2) 
to achieve terminal 1-year seizure remission (1-year TSR). Drug resistant epilepsy 
- 2 - 
(DRE) was defined as two or more seizures per year after trial of two appropriate 
AEDs. Patients who had only one seizure during the previous one year were 
assigned as “epilepsy with rare seizure (ERS)”. 
Results: A total of 34 drug-naïve patients (male 20) were included to the study. 
Mean duration of follow up was 5.88 ± 3.15 years. Pre-treatment baseline mean and 
median seizure frequencies were 4.93 ± 12.63 and 0.85 (1.92) episodes per month, 
respectively. 1-year TSR was achieved in 22 of 34 (64.7%) patients, nine (26.5%) 
patients were diagnosed as DRE, and three (8.82%) patients were as ERS. 1-year 
TSR was achieved in 18 of 34 (52.9%) patients by the first drug regimen and in 
additional four (11.8%) patients by the second drug regimen. Among 16 patients 
who failed to achieve 1-year TSR by the first drug monotherapy, three patients were 
ERS and did not undergo second drug trial. None of nine patients who failed to first 
two drug regimens did achieve 1-year TSR. Univariate analysis of multiple clinical 
variables disclosed that the location of CM in the temporal lobe was the only 
prognostic factor predicting a poor seizure outcome (p = 0.012). 
Conclusion: 1-year TSR was achieved in 64.7% of newly diagnosed patients with 
CRE in a long-term AEDs therapy. Failure to achieve seizure-freedom after 
adequate trials of two AEDs is strongly recommended as criteria for their referral to 
surgical treatment. However, for patients with temporal lobe CRE, a presurgical 
evaluation may be considered appropriate once they failed to an adequate trial of the 
first drug.  
 
Key words: cavernous malformation, epilepsy, medication treatment  
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INTRODUCTION 
Cavernous malformation (CM) is the second most common type of 
vascular malformation. An epileptic seizure is the most common presenting 
symptom of CM, which is followed by focal neurological deficits, acute 
hemorrhage, and headache.
1
 Supratentorial location, cortical involvement and 
archicortical and mesiotemporal location are established risk factors of cavernous 
malformation related epilepsy (CRE).
2
  
A prospective population-based registry reported that 5-year risk of first-
ever seizure after the presentation of incidental CM was 4%, while 5-year risk of 
epilepsy (or second seizure) after first-ever seizure in patients with CM was 94%, 
which has provided a strong evidence for starting antiepileptic drug (AED) therapy 
in patients with a single seizure related to CM.
3
 In this study, 2-year seizure 
remission rate by AED therapy at 5-year follow-up period was 47%, which was 
lower than the 2-year seizure remission rate (68%) from a population-based study in 
- 4 - 
UK.
4
 On the other hand, a large outpatient clinic database found that the seizure-
free rate (SFR) in patients with vascular malformation related epilepsy was 50%, 
which was better than that of patients with normal MRI (42%), due to head trauma 
(30%), cortical dysplasia (24%), and hippocampal sclerosis (11%).
5
 However, long-
term outcomes of AED therapy in a pure group of CRE have not been adequately 
investigated yet, thus any evidence-based guidelines for the management of newly 
diagnosed patients with CRE are not available yet.  
 Surgery of patients with CRE was associated with 70% to 84% of Engel 
Class-1 outcome with earlier surgical intervention being a favorable prognostic 
factor.
6-9
 However, a meta-analysis of surgical outcomes in patients with CRE 
pointed out too much heterogeneity among studies due to differences in patient’s 
inclusion criteria, surgical techniques and presurgical evaluations, or use of different 
classifications of surgical outcomes, and concluded that the clinical usefulness of 
these studies is seriously limited.
10
 Recently, a systemic review comparing surgery 
with medical treatment in patients with CRE failed to show any significant benefits 
of surgery.
11
 Another long-term outcome study in patients with newly diagnosed 
CM indicated significantly worse outcome of early surgery compared with 
conservative management in newly diagnosed patients with CM at the assessment 
of 5-year follow-up, which casts a doubt about the benefit of early surgery in 
patients presenting with CRE.
12
  
 
Recent ILAE-report stated that it was not necessary to wait until the rigorous 
criteria of drug resistant epilepsy (DRE) proposed by ILAE
13
 being fulfilled but the 
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failure to an appropriately conducted first drug trial should be considered sufficient 
to recommend a presurgical evaluation.
2
 This statement seems to reflect current 
expert’s opinions, which requires a caution for adopting it as evidence-based 
practice guidelines.
14
 Decision about the optimal timing of patient’s referral to 
surgery needs to be individualized and should be based on accurate risk-benefit 
assessment for surgery, which requires reliable longitudinal outcome data of AEDs 
therapy in patients with new onset of CRE. We conducted the investigation to 
identify the clinical courses and related prognostic factors in patients with CRE who 
were newly treated with AEDs therapy at the epilepsy clinic.  
 
MATERIALS AND METHODS  
Patients and treatment 
We conducted a retrospective analysis of Yonsei Epilepsy Registry, which 
is a prospective patient registry to the Yonsei Epilepsy Clinic in Seoul, Korea.
15
 A 
total of 73 patients were registered under the diagnosis of untreated CRE during the 
period between 2000 and 2011. The patient’s inclusion criteria were: (1) well-
established diagnosis of partial epilepsies as defined by the International 
Classification of Epilepsies and Epileptic Syndromes
16
; (2) presence of CM by brain 
magnetic resonance imaging (MRI); (3) Electroencephalography (EEG) evaluation; 
(4) lack of any clinical (semiology) or EEG evidence suggesting non-CRE, (5) at 
least one episode of seizure during the previous year before commencing AEDs 
therapy, (6) at least a two-year follow-up. Reasons for exclusion were: (1) previous 
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surgery for CM (n = 13); (2) less than two-year follow-up (n = 11); (3) previous 
AED therapy before their referral (n = 10); (4) Non-CRE (n = 2); (5) no EEG 
evaluation (n = 2); (6) No seizure event during last one year before treatment (n = 1). 
The age at seizure onset, gender, duration of illness, seizure frequencies 
before and after treatment, EEG and brain MRI findings, prescribed AEDs and 
surgical information were documented. Epilepsy syndrome and seizure 
classification
16
 were based on thorough clinical assessments (i.e., history taking, 
neurologic examination, ictal semiology, and so on), and careful clinical 
correlations with EEG and brain MRI. Patients usually visited the clinic at one to 
six month intervals and their seizure frequency was assessed at every clinic visit. 
AEDs therapy consisted of initial monotherapy of the first-line drugs (lamotrigine, 
carbamazepine, oxcarbazepine, valproate, topiramate, levetiracetam, and phenytoin) 
for partial-onset seizures. If patients developed seizure recurrences during adequate 
trial of first drug regimen, second drug was chosen and tried either in substitution 
monotherapy or combination therapy. If the first drug was discontinued due to 
emergence of adverse effects at lower doses than its usual target dose, the drug trial 
was not considered adequate to be counted as the first drug regimen. Caring 
epileptologists were fully responsible for the treatment regimens during the follow-
up period.  
 
Evaluations and assessments 
EEG and brain MRI were acquired in all patients. Brain MRI sequences included 
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T2-weighted axial slices with a regular high-resolution MRI unit (1.5-tesla or 3.0-
Tesla Sigma)
17
; range of in-plane resolution 0.449 - 0.898 mm; slice thickness 1 - 5 
mm; slice spacing 1 - 2 mm. Gradient recalled echo sequences were not routinely 
applied but only in a few selected cases.  
A neuroradiologist and a neurologist evaluated the MRI data for each 
patient independently to assess the number, side, localization, and maximal diameter 
of CM by using a predefined form, which was followed by a joint session for 
harmonizing the differences in interpretation. The location of CM was classified as 
temporal, frontal, parietal, occipital and infratentorial lesions. In patients with 
multiple CMs, the localization of epileptogenic lesion was determined to the lobe 
harboring the lesion correlating with the patient’s seizure descriptions, EEG features, 
or the largest lesion if their correlations were not clear. The maximal diameter of 
CM without the hemosiderin rim was measured and divided into ≤20 mm and >20 
mm. Baseline seizure frequency was defined as monthly seizure frequency by 
counting seizure numbers during the last three months in patients having monthly 
seizures or during the last 12 months in patients with less frequent seizures before 
the commencement of AEDs therapy. After AEDs therapy, seizure frequency was 
calculated at each clinic visits and assessed annually as seizure-free or not seizure-
free until the last follow-up visit. 1-year seizure remission (SR) was defined as 
freedom from seizure for 12 months during each year of follow-up, whereas 1-
year terminal seizure remission (TSR) indicated no seizure during the last one year 
of follow-up. If there was only one seizure during the year, we categorize them as 
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epilepsy with rare seizure (ERS). If there were two or more seizure recurrences 
during one year after adequate trial of second drug regimen, DRE was diagnosed. 
Patients were divided into two groups according to the achievement of 1-year TSR; 
patients who have achieved 1-year TSR were assigned to Group-1, whereas Group-
2 included patients who had seizure relapses during the last one year of follow up 
(patients with DRE and ERS).  
 
Statistics 
Data processing and analysis were performed with SPSS Version 18.0 for 
Windows. Data were expressed as mean standard deviation (SD), and median values 
were calculated. For subgroup analysis, the Chi
2
 test (or Fisher’s exact test) and 
independent two-sample t-test were performed. Significance was assumed for all 
comparisons at the two-sided p-value of ≤0.05.  
 
RESULTS 
Demography and Clinical Characteristics 
Among 34 patients, 20 (58.8%) were male. Mean age of patients at their 
presentation to the epilepsy clinic was 42.2 year-old (SD ± 16.62) and the mean age 
of seizure onset was 35.2 year-old (SD ± 17.09) with the mean duration of epilepsy 
being 6.09 years (SD ± 8.64). Mean baseline seizure frequency was 4.93 episodes 
(SD ± 12.63) per month and median seizure frequency was 0.85 (1.92) episodes per 
month. Seizure frequency was less than one per month in 18 (52.9%) patients, one 
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or more seizures per month in 14 (41.2%) patients, and daily seizures in two (5.9%) 
patients. Mean duration of follow up was 5.88 ± 3.15 years (range 2-12). CMs were 
located in the frontal lobe in 17 (50.0%) patients, temporal lobe in 15 (44.1%), and 
parietal lobe in two (5.9%) patients. Six patients (17.6%) showed multiple CMs in 
MRI and one of them had a positive family history of CM. Among those with 
multiple CMs, four patients were assigned to the frontal lobe epilepsy and one 
patient each to the temporal lobe and the parietal lobe epilepsy on the basis of 
clinical-EEG and MRI correlations (n = 3) or location of the largest lesion (n = 3). 
The mean size of CM was 1.2 ± 6.29 cm (range 0.4-3.0). Twenty two (64.7%) 
patients achieved 1-year TSR, thus assigned to Group-1. Among those, 18 (52.9%) 
patients achieved 1-year TSR by the first drug monotherapy and four patients 
(11.8%) did so by the second drug regimen. AEDs were withdrawn in two patients 
after prolonged seizure remission by their strong desire to be free of AEDs, and 
have been remaining seizure-free for three and five years each. Among 12 (35.3%) 
patients who were assigned to Group-2, six patients were under duotherapy, two 
patients under triple drug therapy and one patient was taking five drugs in 
combination. Remaining three patients had ERS and were kept on the first drug 
monotherapy after further dose escalations. Lamotrigine was the most frequently 
used AED for monotherapy, whereas various combinations of AEDs were used for 
duo- or triple drug therapy.  
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Outcome of AEDs Therapy 
Nineteen patients achieved 1-year SR by the first drug treatment but seizures 
relapsed in four of them. Among those four patients who did relapse, two patients 
were ERS and were followed-up with gradual dose-escalations of the first drug, 
whereas two other patients underwent trials of second drug regimen with 
achievement of 1-year TSR in one and failure to achieve seizure remission in the 
other. Among 15 patients who have failed to the first drug, three patients achieved 
1-year TSR with a dose escalation of the first drug and another three patients by the 
trial of the second drug regimen. 1-year TSR and cumulative 1-year SR were 64.7% 
(22/34) and 73.5% (25/34), respectively. Nine patients (26.5%) continued to have 
seizure recurrences despite of adequate trials of two AEDs, thus satisfied the criteria 
of DRE. 1-year TSR was achieved by the first drug regimen in 18 patients (52.9%). 
The second drug regimen was successful in four of 13 (30.8%) patients who failed 
to the first drug. None of patient who failed to the adequate trial of second drug 
regimen achieved 1-year TSR by further drug trials. Remaining three patients who 
had ERS during the first drug trial were kept on the first drug monotherapy after 
progressive dose-escalations by the judgment of caring physicians (Figure 1).  
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Figure 1 Flowchart of overall seizure outcome.  
Abbreviation: First year SR=seizure remission during the first one year; Non first 
year SR=not seizure free during the first one year; 1-year TSR=seizure free during 
the last one year of follow-up; ERS=epilepsy with rare seizure (only one episode of 
seizure relapse during the previous one year of follow-up); DRE=drug resistant 
epilepsy (two or more seizures during the previous one year of follow-up); *=The 
patients achieved 1-year TSR by the first drug regimen; **=The patients achieved 
1-year TSR by the second drug regimen.   
 
 
Clinical variables related with the outcome of AEDs therapy  
We conducted an univariate analysis of multiple clinical variable to assess 
their correlations with the long-term outcomes of AEDs therapy, which were age of 
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seizure onset, seizure frequency before treatment, duration of illness, location, 
numbers, and size of CM, and EEG features. Among those, location of CM was the 
only one prognostic factor significantly correlating with the outcome of AEDs 
therapy (Table 1).  
 
Table 1 Comparison between characteristics of the Group 1 and Group 2   
Patients Group 1 (N = 22) Group 2 (N = 12) 
 
 
Mean ± SD Mean ± SD p-value 
Age (year-old) 38.27 ± 17.47 29.50 ± 115.47 0.144 
Seizure duration (year) 5.32 ± 3.08 6.92 ± 3.15 0.168 
Seizure frequency (monthly) 4.33 ± 9.89 6.04 ± 17.02 0.753 
 
Number Number 
 
Sex (M/F) 14/8 6/6 0.487 
EEG findings    
 
Normal/Abnormal 11/11 6/6 1.000 
 
IEDs (+)/(-) 9/13 5/7 1.000 
Single/Multiple lesion 16/6 12/0 0.069 
Size of lesion ≤2.0cm 19 12 0.537 
Temporal/Extratemporal location 6/16 9/3 0.012 
Abbreviation: SD=standard deviation; EEG=electroencephalography; M=male; 
F=female; IED= interictal epileptiform discharges. 
* Statistically significant at p ≤0.05. 
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Temporal lobe CM was more common in patients assigned to Group 2 (9 
of 15 patients), whereas extratemporal location of CM were much more common in 
Group 1 (16 of 19 patients), which were statistically significant (p=0.010) (Table 2). 
None of other clinical variables showed any significant correlations with the 
location of CM using the logistic regression. Among 15 patients with temporal CRE, 
four (26.7%) achieved 1-year TSR by the first drug treatment compared to 14 of 19 
(73.7%) patients with extratemporal CRE (p=0.006). Among 8 patients with 
temporal CRE who underwent the trial of second drug regimen, 2 patients (25%) 
achieved 1-year TSR, whereas 2 of 5 (40%) patients with extratemporal CRE did 
achieve 1-year TSR by the second drug regimen.  
 
Table 2 Comparison between characteristics of the temporal located CM and 
extratemporal located CM 
 
Temporal CM 
(N = 15) 
Extratemporal CM 
(N = 19) 
 
 
Mean ± SD Mean ± SD p-value 
Age (year-old) 36.27 ± 18.26 34.32 ± 16.57 0.750 
Seizure duration (year) 6.40 ± 2.77 5.47 ± 3.45 0.390 
Seizure frequency (monthly) 9.03 ± 18.09 1.69 ± 3.60 0.143 
Size of lesion (mm) 10.34 ± 5.07 13.51 ± 6.92 0.133 
Outcomes Number Number  
1-year TSR 6 16  
DRE 6 3 0.010 
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ERS 3 0  
TSR by the first drug 4 14 0.006 
TSR by the second drug 2 2 1.000 
Abbreviation: N=number; SD=standard deviation; CM=cavernous malformation; 
TSR=terminal seizure remission; DRE=drug resistant epilepsy; ERS=epilepsy with 
rare seizure. 
* Statistically significant at p ≤0.05. 
 
Postoperative seizure outcome  
Five patients with CRE underwent epilepsy surgery after the failure of 
second drug regimen. All of them had temporal CRE and complete resection of CM 
was undertaken. Two patients underwent extensive lesionectomies consisting of 
resection of the lesion and the surrounding epileptogenic cortex indicated by 
intraoperative electrocorticography. In remaining three patients, resections of the 
lesion and surrounding hemosiderin rim were performed without intraoperative 
electrocorticography. All patients achieved Engel Class-1 outcome and no 
permanent neurological deficits were encountered after surgery. AEDs were 
successfully discontinued in two patients without any recurrences of seizure (Table 
3). 
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Table 3 The patients who underwent surgical intervention for CM 
 
Patient 
No. 
Sex/ 
Age 
Seizure 
frequency*   
Size of CM 
(mm) 
Surgery 
modality 
Engle  
Current 
AED 
1 F/30 0.7 11.00  
Extensive 
lesionectomy 
1A None 
2 M/22 0.7 10.09  Lesionectomy 1D CBZ 
3 M/21 2 17.00  
Extensive 
lesionectomy 
1A LTG 
4 F/53 60 14.42 Lesionectomy 1A 
CBZ 
VPA 
5 M/23 1 4.19  Lesionectomy 1A None 
Abbreviation: No=number; F=female; M=male; CM=cavernous malformation; 
AED=Antiepileptic drugs; CBZ=carbamazepine; LTG=lamotrigine; VPA=valproate; 
*=Seizure frequency per month during last 3 months before treatment  
 
Follow-up brain MRI 
Of 34 patients, 20 patients including four patients with multiple CMs 
underwent follow-up brain MRI. MRI was repeated as a routine follow-up 
procedure in 15 patients (9 patients were in 1-year TSR at follow-up MRI) and for 
evaluation of seizure recurrence of seizures in five patients. Mean duration of 
follow-up was 2.3 years (range 0.5-13.0). Brain MRI showed no significant interval 
changes in 18 patients (90.0%) including six patients with DREs. Two patients with 
multiple CMs in initial MRI showed enlargement of CMs in follow-up MRI (risk of 
10.0% per person year of exposure) (Table 4). One patient of them repeated brain 
MRI twice. The first follow-up MRI was repeated to evaluate the seizure relapse 
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and showed development of hemorrhage and enlargement of the CM in the right 
frontal lobe. He became seizure-free with a dose escalation of prescribing drug 
(valproate). After two years, MRI was repeated again because of seizure relapse and 
development of mild weakness of the left leg. MRI demonstrated further 
enlargement of the same lesion which had shown hemorrhage and enlargement in 
previous MRI. He became seizure-free and his left leg weakness was recovered 
after substitution monotherapy with topiramate. Therefore in our study, two of four 
patients with multiple CMs showed dynamic changes of CMs in follow-up MRI but 
none of 15 patients with a single CM.  
 
Table 4 The patients whose lesion changed in repeated brain MRI 
 
Patient 
No. 
Size of 
CM 
(mm)* 
Location 
of CM*  
Reason** Interval+ MRI changes Management 
1 9.47 Frontal 
Seizure 
relapse 
7 years 
Enlargement and 
hemorrhage of the lesion 
at the right superior and 
mesial frontal lobe 
Escalation of 
the AED  
   
Seizure 
relapse and 
left leg 
weakness 
9 years 
Enlargement the same 
lesion to 18.20 mm 
Change of the 
AED 
2 12.90 Frontal Routine f/u 3 years 
Enlargement to 17.96 
mm 
No change of 
AED 
Abbreviation: No=number; CM=cavernous malformation; MRI=magnetic 
resonance image; *=Cavernous malformations with multiple lesions were classified 
to the lobe harboring the CM responsible for the patient’s seizure, EEG features, or 
to the largest lesion if their correlations were not clear; **=Reason of repeated brain 
MRI; 
+
= Interval to the first brain MRI 
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Discussion 
Successful seizure outcome was achieved in 18 of 34 (52.9%) patients by 
the first drug monotherapy and in four of 13 (30.8%) patients who had tried second 
drug regimen. None of patients who failed to the second drug regimen achieved 1-
year TSR by further drug trials. Three patients who had ERS during the first drug 
monotherapy did not undergo the trial of the second drug regimen by judgment of 
caring physicians and assigned to Group 2. Josephson et al. reported that 2-year SR 
rate in patients with newly diagnosed CRE was 47% at 5 year follow-up, while it 
was 53.8% (seven of 13 patients) at 5-year follow-up in this study.
3
 In an univariate 
analysis of multiple clinical variables, the lobar location of CM was the single 
important predictive factor associated with the outcome of AEDs therapy with 
temporal CRE being associated with a poor outcome (no 1-year TSR in 9 of 16 
patients) and extratemporal CRE with excellent outcome (1-year TSR in 16 of 19 
patients). Casazza et al. reported that the location of CM in the medial temporal 
lobe was more frequent in patients with refractory CRE
8
, however, we were not able 
to find any meaningful differences in seizure outcomes between the medial and the 
lateral temporal CREs in our patients (data was not shown).  
Initial monotherapy of the first-line drugs is the rule of AEDs therapy in 
patients with newly diagnosed epilepsy. If an adequate trial of the first drug fails to 
control seizures, trials of the second drug regimen either in monotherapy or 
combination therapy is the next step of treatment. Failure of seizure control by 
adequate trials of two AEDs defines the diagnosis of DRE
13
, in which referral to 
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tertiary epilepsy care centers are strongly recommended for further diagnostic 
precision and appropriate therapeutic trials including epilepsy surgery.  
Epilepsy surgery is the most effective but often underutilized therapeutic 
modality for patients suffering from DREs. Randomized controlled trials (RCTs) 
clearly demonstrated the superior outcome of epilepsy surgery compared to that of 
continuing AEDs therapy in patients with refractory TLE.
18,19
 No RTCs for the 
outcome of epilepsy surgery in patients with extra-TLE have been conducted yet, 
however, a meta-analysis have shown that the postsurgical outcome of extra-TLE 
was significantly worse than that of TLE, especially in patients with normal 
MRI.
20, 21
 Presence of focal, resectable lesions in MRI has been found the most 
important factor affecting the postsurgical outcome in patients with DREs. In a 
meta-analysis, SFR after surgery in patients with epilepsy related to focal MRI-
lesions (lesional epilepsies) was 70% compared to 46% of non-lesional epilepsies, 
which was a highly significant difference.
21
 These outcome studies made a basis 
for the recommendation of earlier referral of patients to presurgical evaluation if 
they failed to adequate therapeutic trials of two AEDs and their epilepsy 
syndromes are considered surgically remediable. However, the optimal timing of 
epilepsy surgery in patients with DREs is based on careful risk-benefit assessments 
in individual patients, which may include perceived benefits and risks related to 
surgery and presurgical evaluation, severity of epilepsy, and outcomes of further 
AEDs therapy. In addition, a significant proportion of patients who failed to 
adequate trial of two AEDs may still have a good chance of prolonged seizure 
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remission by further drug trials
22
, which may raise a significant controversy related 
to the optimal timing of epilepsy surgery during the course of AEDs therapy.  
A prospective study found that 73 of 128 (57%) patients who failed to 
previous trials of 2 AEDs achieved 1-year SR, however, 50 (68%) of them 
experienced seizure relapses.
23
 At the end of follow-up for 10.1 years, 3-year TSR 
was achieved in 28 (22%) patients, which was strongly related to the etiology of 
epilepsy; 11% in symptomatic epilepsy vs. 33% in cryptogenic epilepsy (p = 0.003). 
Another long-term observational study in 79 patients who failed to ≥ 2 AEDs 
within 2 years after diagnosis of epilepsy
24
, has shown that 34 (45.3%) patients 
became seizure free at the follow-up of 11.7 years with the neuroimaging features 
being a single predictive factor for the long-term outcome; SFR was 60% in patients 
with normal MRI vs. 9% in patients with abnormal MRI. Therefore, symptomatic 
etiology or MRI-lesions in patients who failed to adequate trials of 2 AEDs seems 
sufficient for consideration of earlier epilepsy surgery if their lesion is surgically 
accessible, while patients with cryptogenic etiology or normal MRI may be better 
off with further systematic AEDs therapy for a higher chance of seizure remission 
as well as less favorable surgical outcomes. The poor outcome of further drug trials 
in our patients who failed to first 2 AEDs is in good agreement with these studies 
and we are in a great favor of the recommendation for earlier surgical evaluations in 
patients who failed to the first two drug regimens.  
Prediction of long-term outcomes in patients who failed to the first AED is 
less clear. A previous study reported that 29 of 72 (42%) patients who failed to the 
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first drug became seizure-free at ≥ 8 years of follow up.25 A recent follow-up study 
of the SANAD trial
26
 reported that 70% of patients who failed to the first drug trial 
achieved 1-year SR at 5 years of follow up and concluded that the predictive 
accuracy of long-term outcome models after first drug failure was relatively low. On 
the other hand, failure to the first drug trial was a strong prognostic factor in 
patients with TLE. Dlugos et al. reported that the failure to the first drug in patients 
with TLE was associated with very high positive (0.89; 95% confidence interval 
0.76 to 0.96) and negative (0.95; 95% confidence interval 0.87 to 0.99) predictive 
values for subsequent drug refractoriness.
27
 Spooner et al. followed 64 children with 
TLE for median 13.7 years and found that a long-term seizure-free outcome was 
achieved in none of 28 children with MRI-lesions compared to 19 of 36 patients 
with normal MRI.
28
 These studies strongly suggest that the long-term outcome of 
AEDs therapy in patients with TLE is different from that of general epilepsy 
populations, thus their failure to the first drug is an important predictive factor for 
persistent pharmacoresistance, especially in cases with associated MRI-lesions in 
the temporal lobe. The assumption seems in good agreement with the results of this 
study, which has shown significantly worse outcome in temporal CRE compared to 
extratemporal CRE (p = 0.006). The responses to the second drug regimen seemed 
also lower in patients with temporal CRE than patients with extratemporal CRE (25% 
vs. 40%, respectively). The difference was not statistically significant due to a small 
number of patients, which should be further investigated in future studies.  
Risk-benefit assessment of epilepsy surgery in patients with drug resistant 
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CRE requires reliable data on postsurgical outcomes. A review of previous surgical 
series
2
 showed Engel class-1 outcome in 70% to 84% of patients, which seemed 
better or at least not worse than that of surgery of TLE. In a direct comparison of 
epilepsy surgery of mesial temporal lobe epilepsy (MTLE) due to hippocampal 
sclerosis (HS) with MTLE due to CM, the latter was associated with a significantly 
better postoperative outcome (SFR in 42% and 82%, respectively; p=0.029), 
however, DREs were more common in patients with MTLE due to HS (88%) than 
MTLE due to CM (36%), which made it as an unfair comparison.
29
 In our study, the 
outcome of lesionectomies in 5 patients who were confirmed to have refractory 
temporal CRE was excellent to achieve Engel class-1 outcome in all patients 
without any permanent new neurological deficits, which was strongly in favor of 
surgery than continuing AEDs therapy in patients suffering from refractory temporal 
CRE. However, it should be stressed that excision of CM is not without risks, 
because comparative studies of the early surgery and the conservative management 
in newly diagnosed patients with CM showed significantly worse outcome in 
patients underwent early surgical excision.
12
 In addition, another comparative 
studies of early surgery and medical treatment in patients with CRE did not show 
any significant differences in seizure outcomes between the two groups.
11
 Therefore, 
any recommendations proposing a surgical excision of CM shortly after its 
diagnosis cannot be justified by currently available evidence.  
Considering the result of AEDs therapy and surgical outcomes of 
refractory TLE in our patients and outcome data from previous studies, different 
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management strategies based on the location of CM seems more appropriate; failure 
to control seizures by adequate trial of first AED in patients with temporal CRE 
may be considered sufficient for their referral to earlier surgery, while second drug 
trial is preferred in patients with extratemproal CRE due to a reasonable chance of 
seizure remission by the second drug trial and possibly higher risks associated with 
extratemporal lobe surgery.  
Routine follow-up MRI in patients with CRE has been recommended 
because CM is considered a dynamic vascular abnormality.
2
 Dynamic changes of 
CM may be related to serial micro- or macro-hemorrhages followed by organization, 
fibrosis, and calcification. We obtained repeat MRIs in 19 patients and found 
enlargement of CMs in two patients with combined lesional hemorrhage in one 
patient, all of whom were harboring multiple CMs. This was in a strong contrast to 
the result of follow-up MRIs in 15 patients with a single lesion, who did not show 
any appreciable changes in the size of CM. The behavior of CM in patients with a 
single CRE may be different and less dynamic than patients carrying multiple CMs 
or patients presenting with hemorrhages and/or focal neurological symptoms. The 
future guidelines of repeating MRI in patients presenting with CRE may require 
further systemic investigations.  
The limitation of current study includes that the number of enrolled patient 
was small and the study was a retrospective observational study, which may be 
associated with significant bias. However, differences in outcomes of AEDs therapy 
between the temporal and the extratemporal CREs were quite striking, supporting 
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different strategies for the planning of optimal management in these two groups of 
newly diagnosed CRE. It is surprising to find that, despite extensive clinical studies 
published in the literature, there have been severe shortages of reliable information 
related to the therapeutic outcomes of CRE. There is urgent need for RCTs for both 
medical and surgical treatments in patients with newly diagnosed CRE. 
 
V. CONCLUSION 
The outcome of AEDs therapy in patients presented with new onset of 
CRE was quite comparable with that of general populations of newly diagnosed 
epilepsy. Location of CM in the temporal lobe was a single important factor 
predicting poor outcome of AEDs therapy. We propose that a failure to an adequate 
first drug trial in patients with temporal CRE may be sufficient for their referral to 
epilepsy surgery, while patients with extratemporal CRE require at least adequate 
trials of two AEDs before their referral to surgery. The probability of finding 
clinically meaningful dynamic changes of CMs in patients with CRE due to a single 
lesion was quite low, which requires future investigations for the cost-benefit 
assessment of routine follow-up MRIs.  
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Abstract (In Korean)  
해면혈관기형 관련 뇌전증 환자를 대상으로 한 약물적 치료의 
장기적 예후 
 
<지도교수 이병인> 
 
연세대학교 대학원 의학과 
 
이 윤 주 
 
목적: 본 연구에서는 새로 진단된 해면혈관기형 관련 뇌전증 환자를 대상
으로 항뇌전증약물을 투여하였을 때 장기적 예후를 분석하고, 적절한 수
술 시기를 제안하고자 한다. 
방법: 본 연구는 2000년부터 2011년까지 신촌 세브란스병원 뇌전증센터
에 방문한 새로이 진단된 해면혈관기형 관련 뇌전증 환자들을 대상으로 
하였다. 모든 환자들은 2년 이상 추적관찰을 하였고, 이전에 다른 병원에
서 수술적 또는 약물적 치료를 하거나 뇌파 또는 뇌 자기공명영상 검사
를 시행하지 않았던 환자, 그리고 발작이 1번 이하로 있었던 경우는 배
제하였다. 환자들은 추적관찰을 한 마지막 1년 동안 발작이 없었던 경우
를 그룹 1, SF군 (seizure free group)으로, 발작이 있었던 경우를 그룹 
2, non SF군 (non-seizure free group)으로 분류하여 그룹간의 차이를 
비교 분석하였다. 약물 저항성 뇌전증은 2번의 적절한 약물로 치료했음
에도 불구하고 1년에 2번 이상의 발작이 있는 경우로 정의하였다. 환자
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가 일 년에 오직 한 번의 발작만 있었던 경우를 “드문 발작”이라고 분류
하였다.  
결과: 총 34명 (남자 20명)의 새로이 진단된 해면혈관기형 관련 뇌전증
환자를 대상으로 하였다. 평균 추적관찰기간은 5.88 ± 3.15년이었고, 치
료 전 마지막 3개월동안의 발작 빈도는 한 달에 4.93 ± 12.63회였다. 추
적관찰을 한 마지막 1년 동안 발작이 없었던 환자는 22명으로 64.7%였
으며 9명 (26.5%)은 약물 저항성 뇌전증으로, 3명 (8.82%)은 드문 발작
으로 분류하였다. 첫 번째 약물에 발작이 없었던 환자는 34명 중 18명 
(52.9%)이었고 추가적으로 4명 (11.8%)은 두 번째 약물을 투여하고 발
작이 없어졌다. 두 번째 약물은 총 16명 중 13명에게 시도하였으며 드문 
발작을 보였던 3명에게는 시도하지 않았다. 두 번째 약물에 실패한 9명
과 드문 발작을 한 3명은 추적관찰을 한 마지막 1년 동안에도 발작이 있
어 그룹 2로 분류되었다. 예후를 예측하는 다양한 변수를 단일변량 분석
을 하였을 때 측두엽에 병변이 있는 경우에만 유일하게 예후가 나빴다. 
(p=0.012) 
결론: 해면혈관기형 관련 뇌전증 환자를 대상으로 장기간 추적관찰을 한 
결과 64.7%에서 추적기간 마지막 1년동안 발작이 없이 유지되었다. 두 
번의 적절한 약물 투여에도 발작이 지속되었던 환자들에게는 수술적 치
료를 하는 것을 강력히 권유하는 것이 바람직하다. 하지만 측두엽에 병변
이 있는 환자에서는 첫 번째 약물에 실패한 경우에도 수술을 위한 검사
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를 진행하는 것을 고려해야 한다.  
 
 
 
 
